February 14, 2022 -- Regen BioPharma is embarking on a development program to commercialize its modified mRNA anticancer vaccine targeting the survivin protein. Regen said it will design and conduct experiments that will form the initial series of preclinical studies required as part of a U.S. Food and Drug Administration investigational new drug submission.
The patented technology is a cellular vaccine that uses a modified mRNA molecule expressing peptides of survivin, which are exposed to dendritic cells. Survivin is the smallest member of the inhibitor of apoptosis family of proteins -- it is involved in inhibiting apoptosis and regulating the cell cycle. Expression of survivin in tumors correlates with not only inhibition of apoptosis and a decreased rate of cell death but also resistance to chemotherapy and aggressiveness of tumors, which makes survivin an important target for cancer vaccines and therapeutics, Regen said.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
